Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Thoughts on Amazon –What Does Its Valuation Tells Us?

Netflix & Amazon Expand in Korea – Not a Coincidence

Okja: The Fight Between Netflix Vs. CJ CGV

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>JMDC's main shareholder Noritsu Koki is selling a 10% stake in JMDC. We will look at the details of the deal. We like the company's fundamentals despite the big deal size and overhang of the shareholder selling down.  The deal scores positively in our ECM Framework and we will participate in the deal.</p>

JMDC's main shareholder Noritsu Koki is selling a 10% stake in JMDC. We will look at the details of the deal. We like the company's fundamentals despite the big deal size and overhang of the shareholder selling down.  The deal scores positively in our ECM Framework and we will participate in the deal.

Ping An Healthcare and Technology (1833 HK)

JMDC Placement: Discovery of Japanese Ali-Health and Ping'an Good Doctor